<DOC>
	<DOC>NCT01398267</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the effect of aleglitazar on renal function, the renin-angiotensin system and the pharmacokinetics of lisinopril in patients with type 2 diabetes mellitus treated with lisinopril. Patients on a stable dose of lisinopril (20 mg daily orally) for 2 weeks will be randomized to receive either aleglitazar (150 mcg orally daily) or placebo in addition to lisinopril for 4 weeks.</brief_summary>
	<brief_title>A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<criteria>Adult male and female patients, 18 to 65 years of age, inclusive Diabetes mellitus Type 2, diagnosed at least 3 months before screening Treated with stable dose of metformin for at least 4 weeks prior to screening Treated with stable dose of Angiotensinconverting enzyme inhibitor (ACEI) for at least 4 weeks prior to screening Body mass index (BMI) 18 to 38 kg/m2, inclusive Positive for HIV1, HIV2, hepatitis B or hepatitis C infection Pregnant or lactating females Type 1 diabetes or secondary from of diabetes History or evidence of proliferative diabetic retinopathy or clinically significant neuropathy Clinically significant hepatic disease Clinically significant renal impairment History or evidence of clinically significant cardiovascular disease or disorder Acute infection or current malignancy requiring treatment except for excised basal cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>